SecurityCAA / CalAtlantic Group, Inc. (128195104)
President & CEONICHOLSON LARRY T
Form 4 Count311
Form 8-K Count58
Form 10-Q Count18
Form SC 13G/A Count17

SEC Filings - 10K, 8K, Annual Reports

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CalAtlantic Group, Inc.


DateFormTitle
2018-02-26 15-12B CAA / CalAtlantic Group, Inc. 15-12B
2018-02-13 8-K CAA / CalAtlantic Group, Inc. 8-K (Current Report)
2018-02-08 SC 13G CAA / CalAtlantic Group, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)
2018-02-08 SC 13G CAA / CalAtlantic Group, Inc. / VANGUARD GROUP INC - 3G (Passive Investment)
2018-02-08 SC 13G/A CAA / CalAtlantic Group, Inc. / BlackRock Inc. - 3G/A (Passive Investment)
2018-02-08 SC 13G/A CAA / CalAtlantic Group, Inc. / BlackRock Inc. - 3G/A (Passive Investment)
2018-02-05 8-K CAA / CalAtlantic Group, Inc. FORM 8-K (Current Report)
2018-01-10 8-K CAA / CalAtlantic Group, Inc. FORM 8-K (Current Report)
2018-01-10 SC 13G/A CAA / CalAtlantic Group, Inc. / FMR LLC - 3G/A (Passive Investment)
2018-01-10 SC 13G/A CAA / CalAtlantic Group, Inc. / FMR LLC - 3G/A (Passive Investment)
2018-01-05 DEFM14A CAA / CalAtlantic Group, Inc. DEFM14A
2017-11-09 10-Q CAA / CalAtlantic Group, Inc. FORM 10-Q (Quarterly Report)
2017-11-08 8-K CAA / CalAtlantic Group, Inc. FORM 8-K (Current Report)
2017-10-31 SC 13D/A CalAtlantic Group SC 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-10-31 SC 13D/A CalAtlantic Group SC 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-10-31 DEFA14A CalAtlantic Group DEFA14A
2017-10-31 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-10-31 DFAN14A CalAtlantic Group FORM 8-K
2017-08-10 SC 13G/A CalAtlantic Group 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-08-10 SC 13G/A CalAtlantic Group 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-07-28 10-Q CAA / CalAtlantic Group, Inc. FORM 10-Q (Quarterly Report)
2017-07-27 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-06-15 SC 13D/A CalAtlantic Group SC 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-06-15 SC 13D/A CalAtlantic Group SC 13D/A (Activist Acquisition of More Than 5% of Shares)
2017-06-14 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-06-12 424B2 CalAtlantic Group 424B2 (Prospectus)
2017-06-09 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-06-07 424B2 CalAtlantic Group 424B2 (Prospectus)
2017-06-07 FWP CalAtlantic Group FWP
2017-06-06 8-K CalAtlantic Group 8-K (Current Report/Significant Event)
2017-05-10 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-04-28 10-Q CalAtlantic Group FORM 10-Q (Quarterly Report)
2017-04-27 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-04-04 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-03-31 FWP CalAtlantic Group FWP
2017-03-31 DEFA14A CalAtlantic Group DEFINITIVE ADDITIONAL MATERIALS
2017-03-31 DEF 14A CalAtlantic Group DEFINITIVE PROXY STATEMENT
2017-02-28 10-K CalAtlantic Group FORM 10-K (Annual Report)
2017-02-14 SC 13G/A CalAtlantic Group CALATLANTIC GROUP, INC. (Passive Acquisition of More Than 5% of Shares)
2017-02-14 SC 13G CalAtlantic Group 3G (Passive Acquisition of More Than 5% of Shares)
2017-02-14 SC 13G CalAtlantic Group 3G (Passive Acquisition of More Than 5% of Shares)
2017-02-14 SC 13G/A CalAtlantic Group CALATLANTIC GROUP, INC. (Passive Acquisition of More Than 5% of Shares)
2017-02-08 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)
2017-04-06 LETTER CalAtlantic Group ER
2017-01-23 SC 13G/A CalAtlantic Group 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-01-23 SC 13G/A CalAtlantic Group 3G/A (Passive Acquisition of More Than 5% of Shares)
2017-04-06 CORRESP CalAtlantic Group ESP
2017-04-06 LETTER CalAtlantic Group ER
2016-10-28 10-Q CalAtlantic Group FORM 10-Q (Quarterly Report)
2016-10-26 8-K CalAtlantic Group FORM 8-K (Current Report/Significant Event)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

CUSIP: 128195104